2021
DOI: 10.1200/go.20.00511
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: PURPOSE To present a summary of the recommendations for the treatment and follow-up for metastatic castration-resistant prostate cancer (mCRPC) as acquired through a questionnaire administered to 99 physicians working in the field of prostate cancer in developing countries who attended the Prostate Cancer Consensus Conference for Developing Countries. METHODS A total of 106 questions out of more than 300 questions addressed the use of imaging in staging mCRPC, treatment recommendations across availability and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
5
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(5 citation statements)
references
References 51 publications
0
5
0
Order By: Relevance
“…Additional reports have empirically proven that CSCs isolated from PCa are responsible for self-renewal and tumor initiation 11 , and exhibit drug resistance 8 , 12 . In patients with metastatic castration-resistant prostate cancer (mCRPC), limited treatment options are available, none of which are curative 13 . Typically, patients are treated with docetaxel and later cabazitaxel.…”
Section: Introductionmentioning
confidence: 99%
“…Additional reports have empirically proven that CSCs isolated from PCa are responsible for self-renewal and tumor initiation 11 , and exhibit drug resistance 8 , 12 . In patients with metastatic castration-resistant prostate cancer (mCRPC), limited treatment options are available, none of which are curative 13 . Typically, patients are treated with docetaxel and later cabazitaxel.…”
Section: Introductionmentioning
confidence: 99%
“…Prostate cancer is ‐ after skin malignancies ‐ the second most common cancer and the most one in males 1,2 . 15% of men worldwide are diagnosed with it at some point during their life 3 . Risk factors include genetic predisposition, that is, genetic aberration or family history of prostate cancer, 4,5 obesity, 6 hypertension, 7 and elevated testosterone blood levels 8 .…”
Section: Introductionmentioning
confidence: 99%
“…A definitive diagnosis of prostate cancer is obtained via a biopsy of the prostate and subsequent staging of the tumor by its microscopic appearance using the Gleason score 14 ranging from 2 (low risk) to 10 (high aggressiveness and risk). The course of treatment of the tumor is then decided based on the Gleason score obtained 3 …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Despite favourable response to initial treatment, many men with PC then experience progression due to treatment resistance [2]. Metastatic disease is the leading cause of death from PC, with an overall survival (OS) of 16-18 months on average after disease progression [2,3].…”
Section: Introductionmentioning
confidence: 99%